# MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

> **NCT00443703** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 352 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** MK0518 (raltegravir)
- **DRUG:** Comparator: KALETRA™ (lopinavir (+) ritonavir )
- **DRUG:** Comparator: placebo
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00443703
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 352 (ACTUAL)
- **Why stopped:** primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00443703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00443703, "MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00443703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*